Skip to main content
. Author manuscript; available in PMC: 2013 Sep 1.
Published in final edited form as: Cancer Lett. 2012 Feb 14;322(1):58–69. doi: 10.1016/j.canlet.2012.02.005

Fig. 3.

Fig. 3

Everolimus inhibits mTORC1 but activates ERK pathway in K-Ras mt PDAC cells. Everolimus treated or untreated K-Ras wt and mt PDAC cell lines, as indicated on the top of the panel, were examined by western blotting using antibodies to the unphosphorylated and phosphorylated (p-) proteins in the mTORC1 (A) and Raf-ERK pathway (B), as indicated to the left of the panel.